0
Abstract: Poster Presentations |

EFFECT OF PULMONARY DYSFUNCTION ON SURVIVAL AND PERFORMANCE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER FREE TO VIEW

Sevin Baser, MD*; Amir Onn, MD; Carlos A. Jimenez, MD; Georgie A. Eapen, MD; Vickie R. Shannon, MD; Leendert Keus; Rodolfo C. Morice, MD; E. Lin
Author and Funding Information

University of Texas, MD Anderson Cancer Center, Houston, TX


Chest


Chest. 2005;128(4_MeetingAbstracts):335S. doi:10.1378/chest.128.4_MeetingAbstracts.335S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  To evaluate the effect of FEV1 (% of predicted) at the time of diagnosis on survival and performance status for patients with NSCLC.

METHODS:  Retrospective analysis of patients with NSCLC referred to our pulmonary function test laboratory between January 2001 and November 2001. Clinical characteristics, smoking history, comorbidities, survival, pulmonary function tests, and performance status (ZUBROD) at baseline, 6 months and 1 year were reviewed.

RESULTS:  We studied 206 patients (M=120;F=86) with NSCLC. Mean age was 64.7±10.1 yrs. Fourty-five percent were smokers, 48% were former smokers, and 7% were nonsmokers. Average predicted percent FEV1=70.3%±19.6% (range 25%-123%). Smokers and former smokers averaged 52.4±30 pack-yr. Sixty-three percent of patients had at least one type of comorbidity; DM 15 (7%), HTN 66 (32%), CAD 47(23%). Also 59 (29%) patients had other type of malignancies. The histologic types were; Adenocarcinoma 87(42%), squamous 72(35%), large cell 43(21%), and BAC 4(2%). The stages of patients were IA:28 (14%), IB:27(13%), IIA:8(4%), IIB:31(15%), IIIA:48(23%), IIIB:39(19%) and IV:25(13%). When corrected for tumor stage, comorbidities, and age there was no significant association between initial FEV1% and patients’ survival and change of their performance status.

CONCLUSION:  Pulmonary dysfunction measured by FEV1 % of predicted at the time of diagnosis did not independently affect survival or change in performance status for patients with NSCLC.

CLINICAL IMPLICATIONS:  Degree of pulmonary dysfunction measured by FEV1 is important for selection and outcome of surgically treated patients, but is not a determinant factor of performance and survival for patients with NSCLC overall.

DISCLOSURE:  Sevin Baser, None.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543